The 156 participants were randomised to once-daily etrasimod 1 mg (n=52), 2 mg (n=50), or placebo (n=54); 90% of patients completed the study. At week 12, etrasimod 2 mg, compared with placebo, resulted in significantly higher rates of:
- endoscopic improvement (43.2% vs 16.3%; P=0.003);
- histological improvement (31.7% vs 10.2%; P=0.006);
- histological remission (19.5% vs 6.1%; P=0.027).
Mucosal healing (defined as both endoscopic improvement and histological remission) was seen in 19.5% and 4.1% of patients treated with etrasimod 2 mg and placebo, respectively (P=0.010). The authors think mucosal healing may prove to be an achievable and objective measure of drug efficacy in ulcerative colitis induction studies.
- Peyrin-Biroulet L, et al. ECCO 2019, OP09.
Posted on
Previous Article
« Ustekinumab as maintenance therapy and with shortened interval Next Article
The costs and benefits of biologicals »
« Ustekinumab as maintenance therapy and with shortened interval Next Article
The costs and benefits of biologicals »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
Topical review
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy